These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 15029179)

  • 1. Cancer: survival pathways meet their end.
    McCormick F
    Nature; 2004 Mar; 428(6980):267-9. PubMed ID: 15029179
    [No Abstract]   [Full Text] [Related]  

  • 2. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy.
    Wendel HG; De Stanchina E; Fridman JS; Malina A; Ray S; Kogan S; Cordon-Cardo C; Pelletier J; Lowe SW
    Nature; 2004 Mar; 428(6980):332-7. PubMed ID: 15029198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TORward AKTually useful mouse models.
    Mellinghoff IK; Sawyers CL
    Nat Med; 2004 Jun; 10(6):579-80. PubMed ID: 15170198
    [No Abstract]   [Full Text] [Related]  

  • 4. Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt.
    Asnaghi L; Calastretti A; Bevilacqua A; D'Agnano I; Gatti G; Canti G; Delia D; Capaccioli S; Nicolin A
    Oncogene; 2004 Jul; 23(34):5781-91. PubMed ID: 15208671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells.
    Riesterer O; Zingg D; Hummerjohann J; Bodis S; Pruschy M
    Oncogene; 2004 Jun; 23(26):4624-35. PubMed ID: 15064712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
    Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug resistance mediated by survival- and growth-promoting signaling pathways].
    Fujita N
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):567-71. PubMed ID: 19381028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphatidylinositol 3-kinase (PI-3K)/Akt but not PI-3K/p70 S6 kinase signaling mediates IGF-1-promoted lens epithelial cell survival.
    Chandrasekher G; Sailaja D
    Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3577-88. PubMed ID: 15452065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53.
    Mungamuri SK; Yang X; Thor AD; Somasundaram K
    Cancer Res; 2006 May; 66(9):4715-24. PubMed ID: 16651424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Akt activation protects pancreatic beta cells from AMPK-mediated death through stimulation of mTOR.
    Cai Y; Wang Q; Ling Z; Pipeleers D; McDermott P; Pende M; Heimberg H; Van de Casteele M
    Biochem Pharmacol; 2008 May; 75(10):1981-93. PubMed ID: 18377870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway.
    Portis T; Longnecker R
    Oncogene; 2004 Nov; 23(53):8619-28. PubMed ID: 15361852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting mTOR: something old, something new.
    Garber K
    J Natl Cancer Inst; 2009 Mar; 101(5):288-90. PubMed ID: 19244168
    [No Abstract]   [Full Text] [Related]  

  • 13. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
    Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
    Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversing drug resistance in vivo.
    Wendel HG; Lowe SW
    Cell Cycle; 2004 Jul; 3(7):847-9. PubMed ID: 15190216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initiation of mRNA translation in oncogenesis: the role of eIF4E.
    Montanaro L; Pandolfi PP
    Cell Cycle; 2004 Nov; 3(11):1387-9. PubMed ID: 15492504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular targeting: PI3 kinase pathway.
    Dancey JE
    Ann Oncol; 2004; 15 Suppl 4():iv233-9. PubMed ID: 15477314
    [No Abstract]   [Full Text] [Related]  

  • 17. [16th EORTC-NCI-AACR symposium on new molecular targets and cancer therapeutics].
    Lavelle F;
    Bull Cancer; 2004 Dec; 91(12):985-8. PubMed ID: 15634640
    [No Abstract]   [Full Text] [Related]  

  • 18. Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma.
    Wang J; Wang J; Lopez E; Guo H; Zhang H; Liu Y; Chen Z; Huang S; Zhou S; Leeming A; Zhang RJ; Jung D; Shi H; Grundman H; Doakes D; Cui K; Jiang C; Ahmed M; Nomie K; Fang B; Wang M; Yao Y; Zhang L
    Blood Cancer J; 2019 Nov; 9(12):95. PubMed ID: 31780660
    [No Abstract]   [Full Text] [Related]  

  • 19. Emerging therapies for colorectal cancer.
    Hezel AF; Ryan DP
    Expert Opin Investig Drugs; 2007 Jun; 16(6):867-76. PubMed ID: 17501698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer drugs: A one-two punch for KRAS-driven cancer.
    Cully M
    Nat Rev Drug Discov; 2015 Sep; 14(9):600-1. PubMed ID: 26272189
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.